Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ARMP Armata Pharmaceuticals Inc
- Stocks
- Healthcare
- NYSEAMERICAN: ARMP
Price (delayed)
$1.29
Market cap
$46.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.52
Enterprise value
$158.42M
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is
Highlights
Armata Pharmaceuticals's EPS has surged by 73% YoY and by 54% QoQ
The company's net income has surged by 73% YoY and by 54% QoQ
The company's quick ratio has shrunk by 77% YoY but it has surged by 52% QoQ
The equity has contracted by 50% YoY but it has grown by 6% from the previous quarter
Key stats
What are the main financial stats of ARMP
Market
Valuations
Earnings
Shares outstanding
36.18M
Market cap
$46.68M
Enterprise value
$158.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
9.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.62
Revenue
$5.17M
Gross profit
$5.17M
Operating income
-$42.44M
Net income
-$18.92M
EBIT
-$8.17M
EBITDA
-$6.85M
Free cash flow
-$39.43M
Per share
Balance sheet
Liquidity
EPS
-$0.52
EPS diluted
-$0.89
Free cash flow per share
-$1.09
Book value per share
-$1.33
Revenue per share
$0.14
TBVPS
$2.29
Total assets
$86.44M
Total liabilities
$134.46M
Debt
$126.52M
Equity
-$48.02M
Working capital
-$36.94M
Debt to equity
-2.63
Current ratio
0.23
Quick ratio
0.32
Net debt/EBITDA
-16.32
Margins
Efficiency
Dividend
EBITDA margin
-132.4%
Gross margin
100%
Net margin
-365.6%
Operating margin
-820.2%
Return on assets
-18.3%
Return on equity
N/A
Return on invested capital
-7%
Return on capital employed
-21.4%
Return on sales
-158%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARMP stock price
How has the Armata Pharmaceuticals stock price performed over time
Intraday
-5.15%
1 week
-10.24%
1 month
35.79%
1 year
-60.43%
YTD
-30.27%
QTD
-11.64%
Financial performance
How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$5.17M
Gross profit
$5.17M
Operating income
-$42.44M
Net income
-$18.92M
Gross margin
100%
Net margin
-365.6%
The company's net margin has surged by 76% YoY and by 52% QoQ
The company's net income has surged by 73% YoY and by 54% QoQ
The revenue is up by 14% year-on-year but it is down by 5% since the previous quarter
ARMP's gross profit is up by 14% year-on-year but it is down by 5% since the previous quarter
Price vs fundamentals
How does ARMP's price correlate with its fundamentals
Growth
What is Armata Pharmaceuticals's growth rate over time
Valuation
What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
9.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.62
Armata Pharmaceuticals's EPS has surged by 73% YoY and by 54% QoQ
The equity has contracted by 50% YoY but it has grown by 6% from the previous quarter
ARMP's price to sales (P/S) is 94% lower than its 5-year quarterly average of 155.5 and 59% lower than its last 4 quarters average of 21.9
The revenue is up by 14% year-on-year but it is down by 5% since the previous quarter
Efficiency
How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's return on sales has surged by 89% YoY and by 73% QoQ
ARMP's return on invested capital has surged by 86% year-on-year and by 73% since the previous quarter
Armata Pharmaceuticals's ROA has soared by 72% YoY and by 53% from the previous quarter
Dividends
What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARMP.
Financial health
How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 36% lower than its total liabilities
ARMP's current ratio has dropped by 80% year-on-year but it is up by 21% since the previous quarter
The company's quick ratio has shrunk by 77% YoY but it has surged by 52% QoQ
The equity has contracted by 50% YoY but it has grown by 6% from the previous quarter
ARMP's debt to equity is up by 30% year-on-year and by 4.4% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.